@Article{or.2026.079551,
AUTHOR = {Emmanuel Naveen Raj, Chia-Jung Li, Shih-Hsuan Cheng, Su-Boon Yong, Zhi-Hong Wen, An-Jen Chiang},
TITLE = {Multi-Omics Identification of UBE2C as a Prognostic Biomarker and Therapeutic Target Linked to Topotecan Sensitivity in Cervical Cancer},
JOURNAL = {Oncology Research},
VOLUME = {},
YEAR = {},
NUMBER = {},
PAGES = {{pages}},
URL = {http://www.techscience.com/or/online/detail/27527},
ISSN = {1555-3906},
ABSTRACT = {<b>Objectives</b>: Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) necessitate the discovery of novel biomarkers for prognostic and therapeutic advancement. This study aims to evaluate the clinical significance of ubiquitin-conjugating enzyme E2C (UBE2C) and its association with the tumor microenvironment (TME) in CESC. <b>Methods</b>: We meticulously sourced CESC data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Gene Expression Omnibus (GEO), leveraging cutting-edge techniques including single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics. Through multifaceted data analysis, we endeavored to unravel the intricate role and potential value of UBE2C in CESC tumorigenesis and progression. <b>Results</b>: Analysis of public datasets confirms UBE2C elevation in CESC tumors, correlating with advanced stages, metastasis, and poor disease-free survival (DFS). Dependency screens and functional enrichment highlight UBE2C’s critical role in cell viability and DNA replication. Notably, multi-omics and spatial transcriptomics reveal a strong link between UBE2C expression and macrophage infiltration (CD63<sup>+</sup>) in tumor regions. Finally, pharmacogenomic profiling and molecular docking identified Topotecan as a potent therapeutic agent with high UBE2C binding affinity. <b>Conclusion</b>: In conclusion, UBE2C expression is associated with cervical cancer progression and correlates with an immunosuppressive macrophage-enriched microenvironment, making it a promising candidate for further investigation in therapeutic intervention.},
DOI = {10.32604/or.2026.079551}
}